Are women with osteoporosis treated with denosumab at risk of severe COVID-19?

Endocrine. 2020 Nov;70(2):203-205. doi: 10.1007/s12020-020-02500-4. Epub 2020 Sep 20.

Authors

Anna Maria Formenti¹, Erika Pedone¹, Luigi di Filippo¹, Fabio Massimo Ulivieri¹, Andrea Giustina²

Affiliations

¹ Institute of Endocrine and Metabolic Sciences, Vita-Salute San Raffaele University and IRCCS San Raffaele Scientific Institute, Milan, Italy.
² Institute of Endocrine and Metabolic Sciences, Vita-Salute San Raffaele University and IRCCS San Raffaele Scientific Institute, Milan, Italy. [email protected].

No abstract available

Publication types

Letter
Comment

MeSH terms

Betacoronavirus
COVID-19
Coronavirus Infections*
Denosumab / adverse effects
Female
Humans
Infections*
Osteoporosis* / drug therapy
Osteoporosis, Postmenopausal* / drug therapy
Osteoporosis, Postmenopausal* / epidemiology
Pandemics*
Pneumonia, Viral*
SARS-CoV-2

Substances

Denosumab